Salud financiera de hoja de balance de Perspective Therapeutics

Salud financiera controles de criterios 5/6

Perspective Therapeutics tiene un patrimonio de los accionistas total de $75.2M y una deuda total de $1.7M, lo que sitúa su ratio deuda-patrimonio en 2.3%. Sus activos y pasivos totales son $97.9M y $22.7M respectivamente.

Información clave

2.3%

Ratio deuda-patrimonio

US$1.73m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.24m
Patrimonio	US$75.18m
Total pasivo	US$22.71m
Activos totales	US$97.89m

Actualizaciones recientes sobre salud financiera

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Mar 19

Recent updates

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Mar 19

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($16.8M) de CATX superan a sus pasivos a corto plazo ($15.7M).

Pasivo a largo plazo: Los activos a corto plazo de CATX ($16.8M) superan a sus pasivos a largo plazo ($7.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CATX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de CATX ha crecido de 0% a 2.3% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CATX tiene suficiente cash runway para 3 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que CATX disponga de suficiente cash runway para 2 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Perspective Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Recent updates

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Isoray, Inc. to Report Q3, 2022 Results on May 10, 2022

Price target decreased to US$1.47

Insufficient new directors

Consensus EPS estimates fall by 15%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CEO & Director exercised options to buy US$64k worth of stock.

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1Q 2021)

Price target decreased to US$1.63

American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131

Full year 2021 earnings released: US$0.033 loss per share (vs US$0.051 loss in FY 2020)

Third quarter 2021 earnings released: US$0.006 loss per share (vs US$0.008 loss in 3Q 2020)

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

CEO & Director exercised options to buy US$345k worth of stock.

Executive Vice President of Sales & Marketing Michael Krachon has left the company

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera